Risk of primary urological and genital cancers following incident breast cancer: a Danish population-based cohort study

被引:1
|
作者
Sundboll, Jens [1 ]
Farkas, Dora Kormendine [1 ]
Adelborg, Kasper [1 ]
Schapira, Lidia [2 ,3 ]
Tamang, Suzanne [3 ,4 ]
Norgaard, Mette [1 ]
Cullen, Mark R. [3 ,4 ]
Cronin-Fenton, Deirdre [1 ]
Sorensen, Henrik Toft [1 ,2 ,3 ]
机构
[1] Aarhus Univ Hosp, Dept Clin Epidemiol, Olof Palmes Alle 43-45, DK-8200 Aarhus N, Denmark
[2] Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA
[3] Stanford Univ, Dept Med, Stanford, CA 94305 USA
[4] Stanford Univ, Stanford Ctr Populat Hlth Sci, Stanford, CA 94305 USA
关键词
Female breast cancer; Second primary cancer; Cohort study; 2ND PRIMARY MALIGNANCIES; WOMEN; TAMOXIFEN; REGISTRY; DIAGNOSIS; MORTALITY; SURVIVAL; QUALITY; SYSTEM; TRENDS;
D O I
10.1007/s10549-020-05879-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The prevalence of breast cancer survivors has increased due to dissemination of population-based mammographic screening and improved treatments. Recent changes in anti-hormonal therapies for breast cancer may have modified the risks of subsequent urological and genital cancers. We examine the risk of subsequent primary urological and genital cancers in patients with incident breast cancer compared with risks in the general population. Methods Using population-based Danish medical registries, we identified a cohort of women with primary breast cancer (1990-2017). We followed them from one year after their breast cancer diagnosis until any subsequent urological or genital cancer diagnosis. We computed incidence rates and standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) as the observed number of cancers relative to the expected number based on national incidence rates (by sex, age, and calendar year). Results Among 84,972 patients with breast cancer (median age 61 years), we observed 623 urological cancers and 1397 genital cancers during a median follow-up of 7.4 years. The incidence rate per 100,000 person-years was stable during follow-up (83 for urological cancers and 176 for genital cancers). The SIR was increased for ovarian cancer (1.37, 95% CI 1.23-1.52) and uterine cancer (1.37, 95% CI 1.25-1.50), but only during the pre-aromatase inhibitor era (before 2007). Moreover, the SIR of kidney cancer was increased (1.52, 95% CI 1.15-1.97), but only during 2007-2017. The SIR for urinary bladder cancer was marginally increased (1.15, 95% CI 1.04-1.28) with no temporal effects. No associations were observed for cervical cancer. Conclusion Breast cancer survivors had higher risks of uterine and ovarian cancer than expected, but only before 2007, and of kidney cancer, but only after 2007. The risk of urinary bladder cancer was moderately increased without temporal effects, and we observed no association with cervical cancer.
引用
收藏
页码:825 / 837
页数:13
相关论文
共 50 条
  • [1] Risk of primary urological and genital cancers following incident breast cancer: a Danish population-based cohort study
    Jens Sundbøll
    Dóra Körmendiné Farkas
    Kasper Adelborg
    Lidia Schapira
    Suzanne Tamang
    Mette Nørgaard
    Mark R. Cullen
    Deirdre Cronin-Fenton
    Henrik Toft Sørensen
    Breast Cancer Research and Treatment, 2020, 184 : 825 - 837
  • [2] Risk of primary urological and genital cancers following incident breast cancer: A Danish population-based cohort study
    Sundboll, Jens
    Farkas, Dora
    Schapira, Lidia
    Tamang, Suzanne
    Norgaard, Mette
    Cullen, Mark
    Cronin-Fenton, Deirdre
    Sorensen, Henrik T.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 79 - 79
  • [3] Risk of primary gastrointestinal cancers following incident breast cancer: A Danish population-based cohort study
    Adelborg, Kasper
    Farkas, Dora K.
    Schapira, Lidia
    Tamang, Suzanne
    Fenton, Deirdre C.
    Cullen, Mark
    Sorensen, Henrik T.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 81 - 81
  • [4] Risk of primary haematologic cancers following incident non-metastatic breast cancer: A Danish population-based cohort study
    Hjorth, Cathrine F.
    Farkas, Dora K.
    Schapira, Lidia
    Cullen, Mark R.
    Sorensen, Henrik T.
    Cronin-Fenton, Deirdre
    CANCER EPIDEMIOLOGY, 2023, 82
  • [5] Risk of primary gastrointestinal cancers following incident non-metastatic breast cancer: a Danish population-based cohort study
    Adelborg, Kasper
    Farkas, Dora Kormendine
    Sundboll, Jens
    Schapira, Lidia
    Tamang, Suzanne
    Cullen, Mark R.
    Cronin-Fenton, Deirdre
    Sorensen, Henrik Toft
    BMJ OPEN GASTROENTEROLOGY, 2020, 7 (01):
  • [6] Risk of thromboembolic and bleeding outcomes following hematological cancers: A Danish population-based cohort study
    Adelborg, Kasper
    Corraini, Priscila
    Darvalics, Bianka
    Frederiksen, Henrik
    Ording, Anne
    Horvath-Puho, Erzsebet
    Rorth, Mikael
    Sorensen, Henrik T.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2019, 17 (08) : 1305 - 1318
  • [7] Risk and Survival of Third Primary Cancers in a Population-Based Cohort of Breast Cancer Patients
    Morais, Samantha
    Goncalves, Elisabete
    Fontes, Filipa
    Rodrigues, Jessica
    Calisto, Rita
    Bento, Maria Jose
    Lunet, Nuno
    BREAST CARE, 2022, 17 (04) : 349 - 354
  • [8] Incident Herpes Zoster and Risk of Dementia A Population-Based Danish Cohort Study
    Schmidt, Sigrun Alba Johannesdottir
    Veres, Katalin
    Sorensen, Henrik Toft
    Obel, Niels
    Henderson, Victor W.
    NEUROLOGY, 2022, 99 (07) : E660 - E668
  • [9] Stroke and risk of cancer: a Danish population-based cohort study
    Skajaa, N.
    Veres, K.
    Troelsen, F. S.
    Petersen, J. D.
    Adelborg, K.
    Sorensen, H. T.
    THROMBOSIS RESEARCH, 2022, 213 : S7 - S7
  • [10] Urticaria and risk of cancer: A Danish population-based cohort study
    Farkas, Dora Kormendino
    Sorensen, Sissel Toft
    Vestergaard, Christian
    Schmidt, Sigrun Alba Johannesdottir
    Lindahl, Lise Maria
    Mansfield, Kathryn
    Langan, Sinead
    Sorensen, Henrik Toft
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 502 - 503